HER2 Test
The HER2 Test is a crucial diagnostic tool in oncology, primarily used to guide treatment decisions for certain types of cancer. It identifies the presence and quantity of the HER2 protein on cancer cells, which can indicate how aggressive a cancer might be and its potential responsiveness to specific therapies.
Key Takeaways
- A HER2 Test detects overexpression of the HER2 protein in cancer cells, most commonly in breast and gastric cancers.
- The purpose of HER2 testing is to determine if targeted therapies, which specifically block HER2, would be effective.
- How is HER2 test done typically involves analyzing a tissue biopsy using methods like IHC or FISH.
- Understanding HER2 test results (positive, negative, equivocal) is vital for personalized treatment planning.
- HER2-positive cancers are often more aggressive but can respond well to HER2-targeted treatments.
What is a HER2 Test: Purpose and Procedure
A HER2 Test is a diagnostic procedure that measures the amount of human epidermal growth factor receptor 2 (HER2) protein on the surface of cancer cells. HER2 is a gene that makes proteins called HER2 receptors, which are involved in cell growth, division, and repair. In some cancers, particularly breast and gastric cancers, the HER2 gene can be amplified, leading to an overproduction of HER2 proteins. This overexpression can cause cancer cells to grow and divide more rapidly.
The primary purpose of HER2 testing is to determine if a patient’s cancer is HER2-positive. This information is critical because HER2-positive cancers tend to be more aggressive but are also highly responsive to specific targeted therapies that block the HER2 protein. For instance, approximately 15-20% of breast cancers are HER2-positive, according to the American Cancer Society. Identifying HER2 status allows oncologists to tailor treatment plans, potentially improving patient outcomes and avoiding ineffective treatments.
How is HER2 test done involves analyzing a tissue sample, usually obtained through a biopsy or surgery. The most common methods used for HER2 testing are:
- Immunohistochemistry (IHC): This method uses antibodies to detect HER2 proteins on the surface of cancer cells in a tissue sample. The results are scored from 0 to 3+, with 3+ indicating HER2 overexpression.
- Fluorescence In Situ Hybridization (FISH): If IHC results are equivocal (1+ or 2+), FISH is often performed. This test looks directly for extra copies of the HER2 gene within the cancer cells’ DNA.
- Dual In Situ Hybridization (DISH) or Chromogenic In Situ Hybridization (CISH): These are alternative gene amplification tests similar to FISH but use different detection methods.
The choice of test and the interpretation of results are typically performed by a pathologist, who then provides a report to the treating oncologist. The procedure is generally safe, involving the standard risks associated with a biopsy.
Interpreting Your HER2 Test Results
Understanding HER2 test results is fundamental for guiding cancer treatment, as they directly influence whether targeted therapies will be effective. Results are typically categorized as HER2-positive, HER2-negative, or equivocal, each carrying distinct implications for treatment strategy. For IHC tests, a score of 3+ indicates HER2-positive, meaning there is a significant overexpression of the HER2 protein. A score of 0 or 1+ is considered HER2-negative, indicating no or very low levels of HER2 protein. A score of 2+ is equivocal, requiring further testing, usually with FISH, to confirm the HER2 status.
For FISH tests, results are reported as positive or negative based on the ratio of HER2 gene copies to copies of chromosome 17 (the chromosome on which the HER2 gene resides). A ratio above a certain threshold (e.g., 2.0) typically indicates HER2 gene amplification, classifying the cancer as HER2-positive. Below this threshold, it is considered HER2-negative.
Here’s a simplified overview of how results are often interpreted:
| Test Method | Result | Interpretation | Treatment Implication |
|---|---|---|---|
| IHC | 0 or 1+ | HER2-negative | Not likely to benefit from HER2-targeted therapy. |
| IHC | 2+ | Equivocal | Requires further testing (e.g., FISH) to confirm HER2 status. |
| IHC | 3+ | HER2-positive | Likely to benefit from HER2-targeted therapy. |
| FISH | Positive | HER2-positive | Likely to benefit from HER2-targeted therapy. |
| FISH | Negative | HER2-negative | Not likely to benefit from HER2-targeted therapy. |
Patients with HER2-positive cancers may be candidates for HER2-targeted therapies, such as trastuzumab, pertuzumab, or lapatinib, which specifically block the HER2 protein and can significantly improve prognosis. Conversely, patients with HER2-negative cancers will not benefit from these specific drugs and will be directed towards other treatment modalities like chemotherapy, hormone therapy, or immunotherapy, depending on other characteristics of their cancer. It is essential for patients to discuss their HER2 test results thoroughly with their healthcare provider to understand the implications for their personalized treatment plan and prognosis.
